lung cancer cell lines we examined. Overexpression of ICAM1 on cancer cells has been shown to promote interactions between cancer cells and NK cells. We therefore revealed that anti-cancer cytotoxicity by MHCindependent γδ T cells were also enhanced on decitabine-sensitized lung cancer cells. 
Okinawa Miyako Hospital, Japan Background and Aims: Pseudomesotheliomatous carcinoma of the lung (PMCL) is a rare entity accounting for less than 1% incidence among all lung cancer and characterized by extensive pleural growth and minor invasion of lung tissue. Herein, we present a case of PMCL finally diagnosed by histopathological examination in addition to 18 
F-FDG
PET/CT scan.
Methods:
A 64-year-old Japanese male with hypertension and chronic thyroiditis visited our hospital complaining of a 3-day history of respiratory distress. He was current smoker (40-pack-year) and worked at the brewing industry for years. On physical examination, he had weak breath sounds and a chest radiograph revealed massive pleural effusion (PE) in the entire right lung field. Thoracentesis identified bloody and exudative PE, suggesting that the patient developed a lung tumor and malignant PE. However, we could not find primary lesion in pulmonary fields after removing PE. Contrast enhance computed tomography of the chest showed pleural thickening and small nodules on parietal and visceral pleura, and 18 F-FDG PET/CT scan also revealed the pleural spread in the right thorax. Therefore, we conducted surgical biopsy of pleural nodules for definitive diagnosis, and thoracoscope showed disseminated white nodules over the right pleura. Finally, pathological examinations confirmed the presence of malignant cells using surgical specimens, and histochemical and immunohistochemical analysis revealed the tumor was pseudomesotheliomatous adenocarcinoma.
Results: According to the previous studies, major pseudomesotheliomatous tumours were adenocarcinoma, and there was relation between increased asbestos concentration in the lung tissue and the appearance of PMCL although the present case had no history of exposure to asbestos. This case was unique at the point that we could identify pseudomesotheliomatous lung cancer in a visual way by thoracoscope.
Conclusion:
Physicians should consider the possibility of PMCL when seeing the patient with bloody and exudative PE, but no apparent mass lesion in the lung. Background and Aims: Metformin use has been reported to reduce cancer risk, and improve survival in lung cancer patients. This study aimed to investigate the effect of metformin use among patients with lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) therapy.
Methods:
A nationwide, population-based case-control study was conducted using the Taiwan National Health Insurance Research Database. From January 1, 2004 to December 31, 2012, a total of 373 metformin and 1,260 non-metformin lung cancer cohorts with diabetes mellitus and EGFR-TKIs treatment were studied.
Results: Metformin use was significantly associated with a reduced risk of death (HR: 0.73, 95% CI: 0.62-0.85, P < 0.001). In addition, metformin use was associated with a significantly longer median progressionfree survival (9.2 months, 95% CI: 8.6-11.7 vs 6.4 months, 95% CI: 5.9--7.2 months, P < 0.001) and median overall survival (33.4 months, 95% CI: 29.4-40.2 vs 25.4 months, 95% CI: 23.7-27.2 months, P < 0.001).
Conclusion:
In conclusion, metformin might potentially enhance the therapeutic effect and increase survival in patients with lung cancer receiving EGFR-TKI therapy. Methods: We retrospectively analyze the treatment and management of adenocarcinoma of the lung in our center. The data analyses were performed using the SPSS Statistics for Windows Version 21.0. In this study, descriptive statistics were employed for selected variables. The findings were presented based on the types and distribution of the data. Categorical data was presented as frequencies and percentages, except age were presented as means and standard deviations.
Comparison of the differences between two sets of radiological measurement within the same group was analyzed using the Wilcoxon
Signed-Rank test
The aim of study is to look at outcome of the management of the patients using Targeted therapy Results: In total, 30 patients were analyzed (12 males, 18 females; median age 58.7 AE 11.17 with 33.3% of them were smokers and 13.3% of them were passive smokers). Tissue biopsies were obtained by pleural biopsy (63.3%), endobronchial biopsy (16.6%), and CT/Ultrasound guided biopsy (23.3%). All of them had EGFR mutations. 19 of them received TKI as the first line chemotherapy where else 6 of them received cisplatin based chemotherapy. Progression free survival (PFS) in the group received TKI were significantly longer (8.4 months) than group which received cisplatin based chemo (6.8 months).
Median target lesions, which treated by TKI's reduced from 48 mm (pretreatment) to 32.5 mm (post treatment. Non target lesions reduced to 15 mm (post treatment) from 23 mm (pretreatment). Many of them develop side effects of skin (46.7%).
Conclusion: There were clinical benefits for patients who received TKI as first line therapy in EGFR mutation patients. 
Methods:
We retrospectively examined non-small cell lung cancer (NSCLC) patients treated with Nivolumab or Pembrolizumab monotherapy. Using immunohistochemistry (IHC), the pre-anti-PD1 treatment tissue specimens were analyzed for a panel of factors involving immune microenvironments, including immune checkpoints (PD-L1, Galectin-9), immune cells (CD4+ T cells, CD8+ T cells, regulatory T cells, M1 and M2 macrophages), antigen presenting machines (MHC class I), and genetic alterations related to immune cells infiltrations (PTEN, beta-catenin). The results were correlated with the treatment response and survival of patients.
Results: Total 25 NSCLC cases were eligible for this study. We found tumor PD-L1, CD4+ T cells, and CD8+ T cells were associated with better objective response rate (ORR), disease control rate (DCR), and progression free survival (PFS). After incorporation of these biomarkers, an immune profile (PD-L1 >0% and either CD4+ T cell ≥ 10% or CD8+ T cell ≥10%) showed a better efficacy to predict ORR, DCR, and PFS. For ORR and DCR, the PPV of a positive immune profile was 54.5% and 90.1%, respectively; the NPV of a negative immune profile was 85.7% and 71.4%, respectively. Through multi-variate analysis, a positive immune profile and ECOG ≤ 1 were independently associated with longer PFS. patients still face problems with drug resistance and disease progression. So far, no patient has been found to small cell lung cancer (SCLC) transformation with an accompanying T790M mutation. This case was reported to explore the clinical manifestation, mechanism, and treatment of this situation mentioned above in lung adenocarcinoma treated with EGFR-TKIs to increase awareness.
We retrospectively analyzed the clinical manifestations and pathological data of one case who had undergone subsequent treatment with gefitinib and osimertinib and then received re-biopsy after disease progression. We searched PubMed databases with the keywords "transformation" "SCLC"and"T790M", and review the relevant literatures.
Results: Pleural puncture cytology and EBUS-TBNA was performed and the 45-year-old women was diagnosed to a EGFR-mutated lung adenocarcinoma. Positron emission tomography-computed tomography and magnetic resonance imaging showed advanced stage IV lung cancer. Then gefitinib was administered at a dose of 250 mg daily which maintained a clinical response for 5 months. After progression, blood NGS showed EGFR T790M mutation, and the patient received osimertinib 80 mg daily. After 5 months, she had a progression again and underwent a re-biopsy, while the results revealed SCLC transformation with an accompanying T790M mutation. She received chemotherapy plus osimertinib, which PFS was 8 months. To our knowledge, this is the first case of SCLC transformation and T790M coexisting after the subsequent first and
